Researchers at the University of São Paulo (USP) have discovered a potential new use for existing osteoporosis medications: combating diseases caused by iron overload. A preliminary study, published in the journal BioMetals, suggests that etidronate and tiludronate, commonly prescribed to inhibit bone reabsorption, can bind to excess iron, reducing cellular stress and preventing damage.
Iron overload, a condition where the body accumulates toxic levels of the metal, can result from genetic disorders like hemochromatosis or as a side effect of treatments like frequent blood transfusions for conditions such as thalassemia. Currently, only three approved medications – known as chelators – exist to treat iron overload, but these often come with unpleasant side effects like nausea and vomiting, hindering patient adherence. This new research offers a potential alternative approach.
The study, stemming from the master’s thesis work of Julia Tiemy Leal Konno under the guidance of Professor Breno Pannia Espósito at USP’s Institute of Chemistry, investigated whether bisphosphonates – a class of drugs used to treat osteoporosis – could act as iron chelators. Bisphosphonates work by inhibiting the breakdown of bone, a process crucial in managing osteoporosis where bone reabsorption exceeds formation, leading to decreased bone density and increased fracture risk.
The researchers hypothesized that the chemical structure of bisphosphonates, rich in phosphates, would have an affinity for iron. They conducted tests in the presence of normal calcium levels, recognizing the competition between iron and calcium within the body and the potential for excess iron to exacerbate osteoporosis. “The idea of our work was to explore this affinity to ‘capture’ the excess iron in the organism,” explained Espósito.
The team tested several bisphosphonates, finding that they were effective in inhibiting oxidation caused by iron in a physiological environment. However, some were found to be more toxic to cells, requiring caution if repurposed as iron chelators. The presence of calcium partially reduced the effectiveness of these compounds, but did not eliminate it. The performance was comparable to a standard chelating agent, demonstrating a strong ability to bind iron and mitigate oxidative stress.
Ranelate de strontium, another antiresorptive medication, was as well tested but did not exhibit chelating capabilities.
Even as these findings offer a promising avenue for treating iron overload, researchers emphasize that it’s still early days. The tests were conducted on human cells in a laboratory setting, representing a “proof of concept” rather than a definitive breakthrough. “Many more studies are needed before these medications can be safely repositioned,” Espósito cautioned.
The study highlights the potential for repurposing existing drugs to address new medical challenges. The researchers’ work builds on the understanding that bisphosphonates, already used to combat bone damage caused by iron overload, could also function as chelators even in the absence of bone disease.
Further research will be crucial to determine the safety and efficacy of using bisphosphonates as a treatment for iron overload in living organisms. Clinical trials will be necessary to assess the optimal dosage, potential side effects, and long-term benefits.
This research offers a glimmer of hope for individuals suffering from iron overload disorders, but it’s important to remember that Here’s a preliminary finding. The journey from laboratory discovery to clinical application is a long one, requiring rigorous testing and validation.
Disclaimer: This article provides informational content about medical research and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
What are your thoughts on the potential for repurposing existing drugs? Share your comments below, and please share this article with anyone who might find it informative.
